Novartis has recently announced that its investigational BYL719 (alpelisib) therapy has reached its primary endpoints in the Phase III Solar-1 clinical trial.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,